Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001420720-24-000054
Filing Date
2024-11-12
Accepted
2024-11-12 16:27:04
Documents
101
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ibio-20240930x10q.htm   iXBRL 10-Q 1627365
2 EX-31.1 ibio-20240930xex31d1.htm EX-31.1 15722
3 EX-31.2 ibio-20240930xex31d2.htm EX-31.2 18747
4 EX-32.1 ibio-20240930xex32d1.htm EX-32.1 10601
5 EX-32.2 ibio-20240930xex32d2.htm EX-32.2 6717
6 GRAPHIC ibio-20240930x10q001.jpg GRAPHIC 75921
7 GRAPHIC ibio-20240930x10q002.jpg GRAPHIC 70535
  Complete submission text file 0001420720-24-000054.txt   9990699

Data Files

Seq Description Document Type Size
8 EX-101.SCH ibio-20240930.xsd EX-101.SCH 73187
9 EX-101.CAL ibio-20240930_cal.xml EX-101.CAL 51774
10 EX-101.DEF ibio-20240930_def.xml EX-101.DEF 448329
11 EX-101.LAB ibio-20240930_lab.xml EX-101.LAB 549181
12 EX-101.PRE ibio-20240930_pre.xml EX-101.PRE 635480
104 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20240930x10q_htm.xml XML 1475072
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-35023 | Film No.: 241448735
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)